Top Markets
#1 MowCat MowCat +48.87%
#2 Velvet Velvet +25.75%
#3 Quack AI Quack AI +21.37%
#4 Derive Derive +19.45%
#5 SkyAI SkyAI +17.12%
#6 Bermuda Shorts Bermuda Shorts +15.70%
#7 Geodnet Geodnet +15.17%
#8 aPriori aPriori +11.70%
#9 Cross Cross +11.69%
#10 Audiera Audiera +11.35%
Coin of the day
MowCat MowCat
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc.

QLGN
Rang in aandelen #35381
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing... Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Aandeelprijs
$2.37
Laatst gesynchroniseerd: 2025-12-15
Marktkapitalisatie
$3.99M
Verandering (1 dag)
-5.58%
Verandering (1 jaar)
24.74%
Land
US
Handel Qualigen Therapeutics, Inc. (QLGN)

Categorie

Healthcare
Winst voor Qualigen Therapeutics, Inc. (QLGN)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Qualigen Therapeutics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Qualigen Therapeutics, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE